KR900016175A - 피페리딘 화합물, 이의 제조방법 및 용도 - Google Patents

피페리딘 화합물, 이의 제조방법 및 용도 Download PDF

Info

Publication number
KR900016175A
KR900016175A KR1019890005606A KR890005606A KR900016175A KR 900016175 A KR900016175 A KR 900016175A KR 1019890005606 A KR1019890005606 A KR 1019890005606A KR 890005606 A KR890005606 A KR 890005606A KR 900016175 A KR900016175 A KR 900016175A
Authority
KR
South Korea
Prior art keywords
alkoxy
alkyl
compound
halogen
cyano
Prior art date
Application number
KR1019890005606A
Other languages
English (en)
Inventor
야코브센 파레
드레에르 외르겐
Original Assignee
타게 호노레
에이/에스 페로산
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 타게 호노레, 에이/에스 페로산 filed Critical 타게 호노레
Publication of KR900016175A publication Critical patent/KR900016175A/ko

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
    • C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D211/20—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by singly bound oxygen or sulphur atoms
    • C07D211/22—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by singly bound oxygen or sulphur atoms by oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pain & Pain Management (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Endocrinology (AREA)
  • Rheumatology (AREA)
  • Hydrogenated Pyridines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Cephalosporin Compounds (AREA)

Abstract

내용 없음.

Description

피페리딘 화합물, 이의 제조방법 및 용도
본 내용은 요부공개 건이므로 전문내용을 수록하지 않았음

Claims (20)

  1. 일반식(I)의 피페리딘 화합물 및 이의 약학적으로 허용되는 산과의 염.
    상기식에서, R3는 하나 이상의 할로겐, C1-6-알콕시, 임의로 치환된 아릴옥시 또는 아릴-C1-6-알콕시, 시아노, 모노 또는 폴리할로겐화 C1-6-알킬, C1-6-알케닐, C1-6-알킬, C3-5-알킬렌 또는 트리플루오로메틸 그룹으로 임의로 치환된 3,4-메틸렌디옥시페닐, 아릴 또는 헤테로 아릴이고, R1은 하나 이상의 시아노, 에스테르, 디알킬아미노, 하이드록시, 아미도, 할로게노, 치환되거나 비치환된 피페리디노, 모르폴리노, 티오 모르폴리노, 디옥솔라닐, 테트라하이드로푸라닐, C1-8-알콕시 또는 C3-8-사이클로알킬 그룹에 의해 치환되거나 비치환된 직쇄 또는 측쇄 C1-8-알킬이며,X는 수소, 할로겐, 트리플루오로메틸, 하이드로시, 시아노 또는 C1-8-알콕시이고, Y는 산소 또는 황원자이며, 단, R3가 하나 이상의 C1-6-알킬, C1-6-알콕시, C3-5-알킬렌, C3-8-사이클로알킬 또는 아르알콕시에 의해 임의로 치환된 3,4-메틸렌 디옥시페닐, 아릴 또는 헤테로아릴이고, 이와 동시에 X가 수소 또는 할로겐인 경우, R1은 비치환된 C1-6-알킬이 아니다.
  2. 제1항에 있어서, R3가 할로겐 또는 C1-6-알콕시로 임의로 치환된 3,4-메틸렌디옥시페닐이거나 C3-5-알킬렌으로 치환된 페닐인 화합물.
  3. 제1항에 있어서, R1이 직쇄 또는 측쇄 C1-8-알킬인 화합물.
  4. 제1항에 있어서, X가 수소, 할로겐, 트리플루오로메틸 또는 C1-6-알콕시인 화합물.
  5. 제1항에 있어서, R3가 할로겐 또는 C1-6알콕시로 임의로 치환된 3,4-메틸렌 디옥시페닐이거나, C3-5-알킬렌으로 치환된 페닐이고, R1이 직쇄 또는 측쇄 C1-8-알킬이며, X가 수소, 할로겐 트리플루오로메틸 또는 C1-6-알콕시인 화합물.
  6. 제1항에 있어서, (-)-트랜스-3-(2-브로모-4,5-메틸렌디옥시펜옥시메틸)-1-부틸-4-(4-플루오로 페닐)-피페리딘 염산염인 화합물.
  7. 제1항에 있어서, (-)-트랜스-4-(4-메톡시 페닐)-3-(3,4-메틸렌디옥시펜옥시메틸)-1-펜틸-피페리딘 옥살레이트인 화합물.
  8. 제1항에 있어서, (+)-트랜스-4-(4-메톡시 페닐)-3-(3,4-메틸렌디옥시펜옥시메틸)-1-펜틸-피페리딘 옥살레이트인 화합물.
  9. 제1항에 있어서, (-)-트랜스-4-(4-플루오로 페닐)-3-(3,4-메틸렌디옥시펜옥시메틸)-1-(3-티아모르폴리닐프로필)-피페리딘 이염산염인 화합물.
  10. a) 일반식(II) 화합물을 일반식(IV) 화합물과 반응시키거나, b) 일반식(III) 화합물을 일반식(V) 화합물과 반응시키거나, c) 일반식(III) 화합물을 브롬과 반응시킨후, 임의로 약학적으로 허용되는 산과의 염을 형성시키는 단계를 포함함을 특징으로 하여, 제1항에 따른 화합물을 제조하는 방법.
    상기식에서, R1, R3, X, 및 Y는 상기에서 정의한 바와 같고, Z는 할로겐과 같은 이탈그룹이며, Y는 산소 또는 항원자이다.
  11. 제1항에 따른 화합물을 약학적으로 허용되는 담체 또는 희석제와 함께 함유하는 약학적 조성물.
  12. 제11항에 있어서, 활성 화합물 1 내지 100mg을 함유하는 경구투여 단위용량형인 약학적 조성물.
  13. 칼슘과다 차단량의 일반식(I)의 피페리딘 화합물을 뇌세포의 칼슘과다증과 관련된 질환의 치료를 필요로 하는 대상에 투여함을 특징으로 하여, 사람을 포함하는 포유동물 뇌세포의 칼슘과다증과 관련된 질환을 치료하는 방법.
    상기식에서, R3는 하나 이상의 할로겐, C1-6-알콕시, 임의로 치환된 아릴옥시 또는 아릴-C1-6-알콕시, 시아노, 모노 또는 폴리할로겐화 C1-6-알킬, C1-6-알케닐, C1-6-알킬, C3-5-알킬렌 또는 트리플루오로메틸 그룹으로 임의로 치환된 3,4-메틸렌디옥시페닐, 아릴 또는 헤테로 아릴이고, R1은 하나 이상의 시아노, 에스테르, 디알킬아미노, 하이드록시, 아미도, 할로게노, 치환되거나 비치환된 피페리디노, 모르폴리노, 티오 모르폴리노, 디옥솔라닐, 테트라하이드로푸라닐, C1-8-알콕시 또는 C3-8-사이클로알킬 그룹에 의해 치환되거나 비치환된 직쇄 또는 측쇄 C1-8알킬이며, X는 수소, 할로겐, 트리플루오로메틸, 하이드록시, 시아노 또는 CSB>1-8-알콕시이고, Y는 산소 또는 황원자이며, 단, R3가 하나 이상의 C1-6-알킬, C1-6-알콕시, C3-5-알킬렌, C3-8-사이클로알킬 또는 아르알콕시에 의해 임로 치환된 3,4-메틸렌 디옥시페닐, 아릴 또는 헤테로아릴이고, 이와 동시에 X가 수소 또는 할로겐인 경우, R1은 비치환된 C1-8-알킬, C1-6-알콕시-C1-8-알킬 또는 C3-8-사이클로알킬-C1-8-알킬이 아니다.
  14. 제13항에 있어서, 허혈증 또는 두부(head) 손상의 치료에 직접적으로 사용되는 치료방법.
  15. 포유동물 뇌세포의 칼슘과다증을 치료하기 위한 제1항에 따른 화합물의 용도.
  16. 허혈증 또는 두부손상을 치료하는데 유용한 약제를 제조하기 위한 일반식(I)의 화합물 또는 이의 약학적으로 허용되는 산과의 염의 용도.
    상기식에서, R3는 하나 이상의 할로겐, C1-6-알콕시, 임의로 치환된 아릴옥시 또는 아릴-C1-6-알콕시, 시아노, 모노 또는 폴리할로겐화 3C1-6-알킬, C1-6-알케닐, C1-6-알킬, C3-5-알킬렌 또는 트리플루오로메틸 그룹으로 임의로 치환된 3,4-메틸렌디옥시페닐, 아릴 또는 헤테로 아릴이고, R1은 하나 이상의 시아노, 에스테르, 디알킬아미노, 하이드록시, 아미도, 할로게노, 치환되거나 비치환된 피페리디노, 모르폴리노, 티오모르폴리노, 디옥솔라닐, 테트라하이드로푸라닐, C1-8-알콕시 또는 C3-8-사이클로알킬 그룹에 의해 치환되거나 비치환된 직쇄 또는 측쇄 C1-8알킬이며, X는 수소, 할로겐, 트리플루오로메틸, 하이드록시, 시아노 또는 C1-8-알콕시이고, Y는 산소 또는 황원자이며, 단, R3가 하나 이상의 C1-6-알킬, C1-6-알콕시, C3-5-알킬렌, C3-8-사이클로알킬 또는 아르알콕시에 의해 임의로 치환된 3,4-메틸렌 디옥시페닐, 아릴 또는 헤테로아릴이고, 이와 동시에 X가 수소 또는 할로겐인 경우, R1은 비치환된 C1-8-알킬이 아니다.
  17. 제1항에 있어서, (+-)-트랜스-3-(3,4-메틸렌디옥시펜옥시메틸)-1-펜틸-4-(3-트리플루오로메틸페닐)-1-펜틸피페리딘 염산염인 화합물.
  18. 제1항에 있어서, (+)-트랜스-3-(2-브로모-4,5-메틸렌디옥시펜옥시메틸)-4-(4-플루오로페닐)-1-펜틸피페리딘 염산염인 화합물.
  19. 제1항에 있어서, (+-)-트랜스-3-(3,4-메틸렌디옥시펜옥시메틸)-1-펜틸-4-(4-펜틸옥시페닐)-피페리딘 염산염인 화합물.
  20. 제1항에 있어서, (+-)-트랜스-3-(4-알릴-2-메톡시펜옥시메틸)-1-부틸-4-페닐피페리딘옥살레이트인 화합물.
    ※ 참고사항 : 최초출원 내용에 의하여 공개하는 것임.
KR1019890005606A 1988-04-28 1989-04-28 피페리딘 화합물, 이의 제조방법 및 용도 KR900016175A (ko)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DK2310/88 1988-04-28
DK231088A DK231088D0 (da) 1988-04-28 1988-04-28 Piperidinforbindelser, deres fremstilling og anvendelse

Publications (1)

Publication Number Publication Date
KR900016175A true KR900016175A (ko) 1990-11-12

Family

ID=8111522

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1019890005606A KR900016175A (ko) 1988-04-28 1989-04-28 피페리딘 화합물, 이의 제조방법 및 용도

Country Status (17)

Country Link
EP (1) EP0339579B1 (ko)
JP (1) JP2857414B2 (ko)
KR (1) KR900016175A (ko)
CN (1) CN1037332A (ko)
AT (1) ATE168375T1 (ko)
AU (1) AU631121B2 (ko)
DE (1) DE68928735T2 (ko)
DK (1) DK231088D0 (ko)
ES (1) ES2118708T3 (ko)
FI (1) FI92822C (ko)
HU (1) HUT55387A (ko)
IL (1) IL89903A0 (ko)
NO (1) NO173826C (ko)
NZ (1) NZ228895A (ko)
PT (1) PT90412B (ko)
ZA (1) ZA893003B (ko)
ZW (1) ZW4889A1 (ko)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK640289D0 (da) * 1989-12-18 1989-12-18 Ferrosan As Ny heterocyklisk kemi
IL98757A (en) * 1990-07-18 1997-01-10 Novo Nordisk As Piperidine derivatives their preparation and pharmaceutical compositions containing them
GB9226111D0 (en) * 1992-12-15 1993-02-10 Smithkline Beecham Plc Madicaments
US6319914B1 (en) 1993-11-05 2001-11-20 Apollo Biopharmaceuticals, Inc. Cytoprotective effect of polycyclic phenolic compounds
US6197833B1 (en) 1995-07-24 2001-03-06 Apollo Biopharmaceutics, Inc. Neuroprotective effects of polycyclic phenolic compounds
US5859001A (en) * 1996-01-11 1999-01-12 University Of Florida Research Foundation, Inc. Neuroprotective effects of polycyclic phenolic compounds
ES2102295B1 (es) * 1994-03-18 1998-04-01 Ferrer Int Nuevos compuestos derivados de la n-benzoilmetil-piperidina.
JP3935502B2 (ja) * 1995-02-28 2007-06-27 第一アスビオファーマ株式会社 アリールピペリジン及びアリールピペラジン誘導体並びにそれらを含む医薬
WO1997003661A1 (en) * 1995-07-24 1997-02-06 University Of Florida Research Foundation, Incorporated Use of non-estrogen polycyclic phenol compounds for the manufacture of a medicament for conferring neuroprotection to cells
ES2117557B1 (es) * 1996-02-29 1999-07-01 Ferrer Int Nuevo procedimiento de obtencion de (-)-trans -n-p-fluorobenzoilmetil-4-(p-fluorofenil)-3- ((3,4-(metilendioxi)fenoxi ) metil)-piperidina.
WO1998003172A1 (fr) * 1996-07-22 1998-01-29 Suntory Limited Derives arylpiperidinol et arylpiperidine et medicaments les contenant
AU710594B2 (en) 1996-07-22 1999-09-23 Asubio Pharma Co., Ltd. Arylpiperidinol and arylpiperidine derivatives and pharmaceuticals containing the same
ATE433959T1 (de) 1997-04-07 2009-07-15 Univ Georgetown Analoge von kokain
US6376672B1 (en) * 1999-04-27 2002-04-23 Hoffmann-La Roche Inc. Naphthalenylmethoxypiperidines as renin inhibitors
WO2001032178A1 (en) * 1999-10-29 2001-05-10 Novo Nordisk A/S Use of 3,4-substituted piperidines
WO2004043921A1 (en) * 2002-11-11 2004-05-27 Natco Pharma Limited Novel process for the preparation of 4-aryl-3-hydroxymethyl-1-methylpiperidines.
US20070142389A1 (en) * 2005-12-20 2007-06-21 Pfizer Inc. Piperidine derivatives
KR20180041751A (ko) * 2015-09-02 2018-04-24 트레베나, 인코포레이티드. 6-원 아자-헤테로고리(6-membered aza-heterocyclic) 함유 델타-오피오이드 수용체 조절 화합물, 그 사용 및 제조 방법
EP3582779B1 (en) 2017-02-17 2024-04-17 Trevena, Inc. 5-membered aza-heterocyclic containing delta-opioid receptor modulating compounds, methods of using and making the same
WO2018152286A1 (en) 2017-02-17 2018-08-23 Trevena, Inc. 7-membered aza-heterocyclic containing delta-opioid receptor modulating compounds, methods of using and making the same

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1422263A (en) * 1973-01-30 1976-01-21 Ferrosan As 4-phenyl-piperidine compounds
EP0190496A3 (en) * 1984-12-13 1987-05-27 Beecham Group Plc Piperidine derivatives having a gastro-intestinal activity
ES2058061T3 (es) * 1985-10-25 1994-11-01 Beecham Group Plc Derivado de piperidina, su preparacion y su uso como medicamento.
IE66332B1 (en) * 1986-11-03 1995-12-27 Novo Nordisk As Piperidine compounds and their preparation and use

Also Published As

Publication number Publication date
JPH01313461A (ja) 1989-12-18
AU3336689A (en) 1989-11-02
JP2857414B2 (ja) 1999-02-17
NO173826B (no) 1993-11-01
AU631121B2 (en) 1992-11-19
NO891762L (no) 1989-10-30
PT90412B (pt) 1994-09-30
NZ228895A (en) 1992-05-26
FI892012A (fi) 1989-10-29
EP0339579A3 (en) 1991-12-18
ES2118708T3 (es) 1998-10-01
ZW4889A1 (en) 1989-08-09
EP0339579B1 (en) 1998-07-15
PT90412A (pt) 1989-11-10
DE68928735D1 (de) 1998-08-20
DK231088D0 (da) 1988-04-28
FI92822C (fi) 1995-01-10
FI892012A0 (fi) 1989-04-27
NO173826C (no) 1994-02-09
EP0339579A2 (en) 1989-11-02
NO891762D0 (no) 1989-04-27
ATE168375T1 (de) 1998-08-15
FI92822B (fi) 1994-09-30
IL89903A0 (en) 1989-12-15
ZA893003B (en) 1989-12-27
DE68928735T2 (de) 1998-11-19
HUT55387A (en) 1991-05-28
CN1037332A (zh) 1989-11-22

Similar Documents

Publication Publication Date Title
KR900016175A (ko) 피페리딘 화합물, 이의 제조방법 및 용도
KR880006193A (ko) 피페리딘 화합물 및 그의 제조 및 용도
FR2692264B1 (fr) Nouvelles piperazines 1,4-disubstituees, leur procede de preparation et les compositions pharmaceutiques les contenant.
RU93005057A (ru) Фармацевтические соединения, производные тиенобензодиазепина, способ их получения, фармкомпозиция и их использование
KR850000462A (ko) [[비스(아릴)메틸렌]-1-피페리디닐]알킬-피리미딘온의 제조방법
DE69100079D1 (de) Naphthalin-derivate, verfahren zu ihrer herstellung und sie enthaltende pharmazeutische zusammensetzungen.
DK623586A (da) Piperidinderivater eller salte deraf og farmaceutiske kompositioner indeholdende forbindelserne
KR890008137A (ko) 3-[4(1-치환된-4-피페라지닐)부틸]-4-티아졸리디노 이의 제조방법 및 약제로서의 이의 용도
PT76450A (de) Spiro/4.(3+n)-2-aza-3-carbonsaeure-derivate verfahren zu ihrer herstellung diese enthaltende mittel und ihre verwendung
PT85014A (fr) Derives de benzo ]b" thiophene et benzo ]b" furannecarboxamides leurs procedes de preparation et les medicaments les contenant
DE3867403D1 (de) L-dopa-derivate oder ihre saeureadditionssalze, verfahren zu ihrer herstellung und ihre verwendung.
ATE268752T1 (de) Aralkyl-1,2-diaminen mit calcimimetischer wirkung und verfahren zu ihrer herstellung
JP2005538111A5 (ko)
KR920701178A (ko) 3-아릴옥사졸리디논 유도체, 그의 제조방법 및 그의 치료 용도
KR890011596A (ko) 불면증 치료용 의약품의 제조에 있어서 1,4-이치환-피페리디닐 화합물의 용도
KR880008997A (ko) 1-(4-하이드록시-3,5-디-3급-부틸벤조일)호모 피페란진, 이의 유도체 이의 제조방법, 이를 함유하는 약품 및 이의 용도
KR900014388A (ko) 에세롤린의 카보네이트 유도체, 이의 제조방법 및 약제로서의 용도
KR940003953A (ko) 1. 4-벤조디옥산 유도체
ATE18549T1 (de) 1-carboxyalkanoylindolin-2-carbonsaeure-ester, verfahren zu ihrer herstellung, pharmazeutische praeparate enthaltend diese verbindungen, sowie ihre therapeutische verwendung.
FR2663328B1 (fr) Derives d'hexahydroazepines, un procede pour leur preparation et compositions pharmaceutiques les contenant.
PE20040668A1 (es) Nuevos derivados de piperidina
KR960017663A (ko) 결합 수용체 길항물질
NO921159L (no) Tiazolidinon- og oksazolidinonderivater, fremgangsmaate til fremstilling derav, samt anvendelse av derivatene som vasodilatorer
KR860000269A (ko) 칼슘길항성의 1-[비스-(4-플루오로페닐)-메틸-4-(3-페닐-2-프로페닐)-헥사하이드로-1h-1, 4-디아제핀의 제조방법및 이것을 함유한 약학적조성물
DE3770321D1 (de) 1,5-benzothiazepinderivate, deren herstellung und deren verwendung in der therapie.

Legal Events

Date Code Title Description
WITN Application deemed withdrawn, e.g. because no request for examination was filed or no examination fee was paid